Your browser doesn't support javascript.
loading
Janus kinase inhibitor, tofacitinib, in refractory juvenile dermatomyositis: a retrospective multi-central study in China.
Zhang, Junmei; Sun, Li; Shi, XinWei; Li, Shipeng; Liu, Cuihua; Li, Xiaoqing; Lu, Meiping; Deng, Jianghong; Tan, Xiaohua; Guan, Wanzhen; Li, Guomin; Wen, Xinran; Liu, Ping; Li, Caifeng.
Afiliación
  • Zhang J; Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
  • Sun L; Department of Rheumatology, Children's Hospital of Fudan University, National Children's Medical Center, No. 399 Wanyuan Road, Shanghai, 201102, China.
  • Shi X; Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
  • Li S; Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
  • Liu C; Department of Nephrology and Rheumatology, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, 450018, China.
  • Li X; Department of Nephrology and Rheumatology, Henan Children's Hospital, Zhengzhou Children's Hospital, Zhengzhou, 450018, China.
  • Lu M; Department of Rheumatology and Immunology, Xi'an Children's Hospital, Xi'an, 710002, China.
  • Deng J; Department of Rheumatology Immunology and Allergy, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, 310003, China.
  • Tan X; Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
  • Guan W; Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, China.
  • Li G; Department of Rheumatology, Children's Hospital of Fudan University, National Children's Medical Center, No. 399 Wanyuan Road, Shanghai, 201102, China.
  • Wen X; Department of Rheumatology, Children's Hospital of Fudan University, National Children's Medical Center, No. 399 Wanyuan Road, Shanghai, 201102, China.
  • Liu P; Department of Rheumatology and Immunology, Xi'an Children's Hospital, Xi'an, 710002, China.
  • Li C; Department of Nephrology and Rheumatology, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, 450018, China.
Arthritis Res Ther ; 25(1): 204, 2023 10 18.
Article en En | MEDLINE | ID: mdl-37853451
ABSTRACT

OBJECTIVES:

Juvenile dermatomyositis (JDM) is a chronic autoimmune disease. Some patients remain in an active state even though they were administrated with a combination of corticosteroid and methotrexate. Existing research has suggested that interferon and Janus kinase played an important role in pathogenesis. Existing research has suggested the efficacy of JAK inhibitors (JAKi). Our retrospective study aimed to investigate the efficacy of tofacitinib in refractory JDM patients.

METHODS:

A total of eighty-eight patients in China who had been diagnosed with JDM and subjected to tofacitinib therapy for over 3 months were retrospectively analyzed. Skin and muscle manifestations were assessed using the Cutaneous Assessment Tool-binary method (CAT-BM), Childhood Myositis Assessment Scale (CMAS), and kinase. Pulmonary function was assessed using a high-resolution CT (computerized tomography) scan and pulmonary symptoms. All patients were subjected to regular follow-up, and core measures were assessed every 3 months after initiation. Furthermore, the data were analyzed using the Wilcoxon single test, Mann-Whitney U test, and chi-square test.

RESULTS:

Compared with the baseline data, skin and muscle manifestations were found significantly improved during the respective follow-up visit. At the most recent follow-up, nearly 50% of patients achieved a clinical complete response and six patients received tofacitinib monotherapy. Sixty percent of patients suffering from interstitial lung disease well recovered on high-resolution CT. Seventy-five percent of patients showed a reduction in the size or number of calcinosis, and 25% of patients showed completely resolved calcinosis.

CONCLUSION:

In this study, the result suggested that tofacitinib therapy exerted a certain effect on skin manifestations, muscle manifestations, interstitial lung disease (ILD), calcinosis, as well as downgrade of medication. In-depth research should be conducted to focus on the correlation between the pathogenesis of JDM and JAKi.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calcinosis / Enfermedades Pulmonares Intersticiales / Dermatomiositis / Inhibidores de las Cinasas Janus Límite: Child / Humans Idioma: En Revista: Arthritis Res Ther Asunto de la revista: REUMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calcinosis / Enfermedades Pulmonares Intersticiales / Dermatomiositis / Inhibidores de las Cinasas Janus Límite: Child / Humans Idioma: En Revista: Arthritis Res Ther Asunto de la revista: REUMATOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China